Ann: Non-Renounceable Rights Issue, page-2

A neutral result imo but I was right about getting the price up a little for a CR.

35% increase in revenue expected for H1 2016, with substantial skew to H2. This demonstrates they're growing the business and FY 2016 revenue should be quite good, even without Benefits8 and Asia playing much part.

On the other hand, need to manage capital carefully, especially while the company's in its relative infancy and dilution can be more of a drag at lower mc/prices.


The Ann regarding board and mgmt changes is interesting, re: Nic Lim focussing more on investor relations and corporate activities. Certainly a little known stock and would be worth the company trying to shop any shortfall around to a boutique microcap fund,